Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sparsentan in combination with SGLT2 inhibitor in IgA nephropathy
NCT05856760Phase 2Completed
- Sponsor
- Travere Therapeutics
- Start
- May 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of sparsentan in immunoglobulin A nephropathy (IgAN), sponsored by Travere Therapeutics. Started May 2023; status: completed.
02
Drugs
sparsentan
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05856760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856760.